
    
      This is a dose escalation study, which means that the first group of patients who enter the
      study will receive a low dose of VELCADE and Docetaxel. If the low dose of VELCADE and
      Docetaxel appears to be safe, then the next group of patients will receive a higher dose of
      VELCADE and docetaxel.
    
  